(2-methoxy-5-(trifluoromethyl)phenyl)methanamine | 400771-42-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-methoxy-5-(trifluoromethyl)phenyl)methanamine
• 英文别名: 2-Methoxy-5-(trifluoromethyl)benzylamine；[2-methoxy-5-(trifluoromethyl)phenyl]methanamine
• CAS: 400771-42-8
• 化学式: C₉H₁₀F₃NO
• 分子量: 205.18
• InChiKey: YZXMLHJVUWEAKE-UHFFFAOYSA-N

物化性质

• 沸点：
  224.4±40.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2-methoxy-5-(trifluoromethyl)phenyl)methanamine 、 2-氯嘧啶-5-羧酸乙酯 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 2.0h， 以200 mg的产率得到ethyl 2-(2-methoxy-5-(trifluoromethyl)benzylamino)pyrimidine-5-carboxylate
  参考文献：
  名称：

  HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY

  摘要：

  该发明涉及用于治疗需要的患者的糖尿病性周围神经病的HDAC抑制剂。本文还提供了一种治疗糖尿病性周围神经病的方法，包括向患者施用HDAC抑制剂的治疗有效剂量。

  公开号：

  US20170114023A1
• 作为产物：
  描述：

  2-甲氧基-5-(三氟甲基)苯甲腈 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (2-methoxy-5-(trifluoromethyl)phenyl)methanamine
  参考文献：
  名称：

  HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY

  摘要：

  该发明涉及用于治疗需要的患者的糖尿病性周围神经病的HDAC抑制剂。本文还提供了一种治疗糖尿病性周围神经病的方法，包括向患者施用HDAC抑制剂的治疗有效剂量。

  公开号：

  US20170114023A1

文献信息

• Compounds and methods for inhibiting phosphate transport
  申请人：Ardelyx, Inc.

  公开号：US09301951B2

  公开（公告）日：2016-04-05

  Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  揭示了具有磷酸盐转运抑制活性的化合物，更具体地说，是肠道顶端膜Na/磷酸盐共转运的抑制剂。这些化合物具有以下结构（I）： 包括立体异构体、药用可接受的盐和前药，其中X、Y、A、R1和R2如本文所定义。还公开了与制备和使用这些化合物相关的方法，以及包含这些化合物的药物组合物。
• Cyclopentyl modulators of chemokine receptor activity
  申请人：——

  公开号：US20020049222A1

  公开（公告）日：2002-04-25

  The present invention is directed to compounds of the formula I: 1 (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and X are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

  本发明涉及具有以下式I:1的化合物（其中R1、R2、R3、R4、R5、R6和X如本文中所定义），其可用作化学趋化因子受体活性的调节剂。特别是，这些化合物可用作化学趋化因子受体CCR-2的调节剂。
• Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors
  申请人：Netz Astrid

  公开号：US20070299074A1

  公开（公告）日：2007-12-27

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及通式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及胍化合物作为5-HT5受体的结合伴侣，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：Netz Astrid

  公开号：US20110237589A1

  公开（公告）日：2011-09-29

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物，其对应的对映异构体、顺反异构体和/或互变异构体以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗由5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
  申请人：ARDELYX, INC.

  公开号：US20140023611A1

  公开（公告）日：2014-01-23

  Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明涉及具有磷酸盐转运抑制活性的化合物，更具体地涉及肠道顶端膜Na/磷酸盐共转运的抑制剂。本发明还涉及与制备和使用此类化合物相关的方法，以及包含此类化合物的制药组合物。